Rns13 Nov 2019 07:09
Integumen announces that it has signed Heads of Terms with Parity plc to enter a multi-year Framework Agreement ("Agreement") to be completed on or before the 18 December 2019 for the supply of Artificial Intelligent ("AI") software across Parity's National Health Service ("NHS"), Central Government and Private Institutional clients.
This Agreement creates an opportunity to cross-sell intelligent data management, extracting value using analytics, with a focus on proving return on investment, to Parity's 150+ institutional clients. The software includes full GDPR compliance with secure cloud data migration from existing legacy systems to a digital workplace through the military grade encryption "Drive4Growth" AI platform powered by Integumen's Rinodrive.
Combined benefits:
· Recurring shared revenue streams for both Parity and Integumen in 2020
· Value-added proposition in demand from Parity clients with c. 3 to 5-year annual contracts
· Immediate access to 150 public and private institutional clients
· Trusted approved vendor for Government and private sectors for over 45 years
· 1,000+ data experts and 100+ enterprise sales and office professionals
· Existing cross-over access to educational institutional research facilities
· Access to multiple industry, public and private sector distribution routes to market
· Well defined roadmap to next level business growth for both Parity and Integumen
Six-month trading update:
In May 2019, Integumen acquired Rinocloud Limited for £3m to enable LabskinAI to uses the Rinodrive AI platform to provide cloud-based data services to Integumen's Top 20 global skincare clients. By the end of June 2019, Rinocloud reached monthly profitability, and over the last six months (May to October) exceeds revenue from Labskin this financial year.
Outlook:
Since 2018, the Company has seen average sales grow from £5k for consumable, one-off sales to 2019 average sales of £50k as a service contract. Heading into 2020, Integumen is engaging with multiple top 20 global skin and personal care companies and believes average sales are likely to range between £100k to £500k for data as a service to skincare R&D framework multi-year agreements, providing good visibility of revenue. Therefore, excluding developments that may arise from Integumen entering into the agreement with Parity Group plc, the Company is guiding 2020 revenues of £4m.